|View printer-friendly version|
|Medtronic Receives Clearance for the SHILLA(TM) Growth Guidance System|
First U.S. Growth Guidance System Cleared to Treat Scoliosis with Children's Needs in Mind
MEMPHIS, TN - Aug. 28, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the 510(k) clearance and launch of the SHILLA(TM) Growth Guidance System. The system is designed for treatment of skeletally immature pediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities.
The SHILLA(TM) Growth Guidance System is a new growth-sparing technology that allows correction of the deformity while maintaining the corrections over time, minimizing the need for periodic lengthening procedures. This is different than current operative treatments, which are distraction based systems that require lengthening every 6 to 9 months.
"Early onset scoliosis is extremely difficult to treat. The current gold standard technique to manage scoliosis long-term is to fuse the spine, but in children who are still growing this can have serious complications," explains SHILLA(TM) Growth Guidance System inventor Dr. Richard McCarthy, an orthopaedic surgeon and faculty member at the University of Arkansas for Medical Sciences/Arkansas Children's Hospital. "Until now we were only able to offer operations which use implants to stabilize the curve in the spine, but these frequently mean twice-yearly surgeries as a child grows. The clearance of the SHILLA(TM) Growth Guidance System marks the first time we can offer effective management of the curvature of the spine while still harnessing the child's natural growth."
The SHILLA(TM) Growth Guidance System utilizes a unique non-locking set screw at the proximal and distal portions of the construct's rods. This specific feature allows the rod to slide through the screw heads as the child's spine grows, while still providing correction of the spinal deformity.
"This clearance advances care for children with early-onset spinal deformities, and for their families and caregivers," said Doug King, vice-president, president of Medtronic Spinal. "We want to thank our surgeon partners and the FDA for helping us bring the SHILLA(TM) Growth Guidance System to an important patient population as we seek to address universal healthcare needs related to outcomes, costs and patient access."
Since receiving CE (Conformité Européenne) Mark in 2012, the SHILLA(TM) Growth Guidance System has been used in 17 countries, on 3 continents.
About the SHILLA(TM) Growth Guidance System
About Medtronic's Spinal Business
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.